Henry Schein Announces Strategic Investment by KKR, Board Changes, and Provides Financial Results and 2025 Guidance Henry Schein, Inc. (Nasdaq: HSIC), the world’s leading provider of health care solutions for office-based dental and medical professionals, today announced a strategic investment…
Cardinal Health Reports Q2 FY25 Results, Raises Outlook Cardinal Health Reports Strong Q2 FY25 Results and Strategic Growth Moves Revenue and Earnings Overview Cardinal Health (NYSE: CAH) has reported a revenue of $55.3 billion for the second quarter of fiscal…
Aetna Better Health of Illinois, a CVS Health company (NYSE: CVS), has introduced three new lifestyle benefits designed to support its Medicaid members enrolled through the HealthChoice Illinois program. These benefits aim to reduce barriers to a healthier lifestyle by…
Cigna Group Reports Strong 2024 Financial Results, Sets 2025 Outlook, and Announces Dividend Increase Global health company The Cigna Group (NYSE: CI) has released its financial results for the fourth quarter and full year 2024, demonstrating continued strength in Evernorth…
Hawthorne Health and RxE2 Partner to Transform Community-Based Clinical Trial Delivery Hawthorne Health, a leader in community-based clinical trial delivery, and RxE2, a pioneer in pharmacist-led clinical trial services, have announced a groundbreaking strategic partnership aimed at revolutionizing the way…
Quanta System, a leader in medical laser technology, is celebrating a significant milestone in 2025: its 40th anniversary. This momentous occasion not only honors the company’s rich history of technological advancements and breakthroughs but also marks the start of an…
Kyowa Kirin and Swixx BioPharma Expand Access to POTELIGEO® for Mycosis Fungoides and Sézary Syndrome in Central and Eastern Europe Kyowa Kirin International (KKI), a fully owned subsidiary of Kyowa Kirin Co. Ltd., in partnership with Swixx BioPharma AG, recently…
Tubulis Advances ADC TUB-030 into Clinical Trials for Advanced Solid Tumors Tubulis, a biopharmaceutical company focused on antibody-drug conjugates (ADCs), announced a significant milestone today with the dosing of the first patient in its Phase I/IIa clinical trial, 5-STAR 1-01…
Osta Therapeutics Expands Leadership Team with Two Industry Experts to Combat Antibiotic Resistance Osta Therapeutics Expands Leadership Team to Tackle Antibiotic Resistance Osta Therapeutics, a biotechnology company focused on developing innovative treatments to combat antibiotic resistance, has announced the appointment…
Ethris Announces Promising Phase 1 Clinical Data for mRNA Therapeutic ETH47 in Asthma Treatment Ethris GmbH, a biotechnology pioneer in the development of next-generation RNA therapeutics and vaccines, has announced promising topline results from its completed Phase 1 clinical trial…
Merz Aesthetics Reveals Global Data on the Link Between Self-Confidence, Self-Affirmation, and Aesthetic Treatments Merz Aesthetics, the world’s largest company in aesthetic medicine, has unveiled the findings of its first global study, “Pillars of Confidence: Global Insights on Aesthetics and…
Owkin, a pioneering AI-biotech company dedicated to transforming drug discovery, development, and diagnostics through agentic AI, has announced the dosing of the first patient in its Phase I clinical trial of OKN4395. The trial commenced on January 22, 2025, and…